MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
Myriad Genetics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Market Cap | $402.69M | $197.05M |
| Enterprise Value | $408.19M | $106.56M |
| PS Ratio | 0.50 | 3.93 |
| PB Ratio | 1.33 | 2.14 |
| P/TBV Ratio | 3.42 | 2.46 |
| P/OCF Ratio | 52.30 | 13.78 |
Enterprise value
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| EV / Sales | 0.51 | 2.69 |
Income (trailing twelve months)
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Revenue | $806.60M | $57.94M |
| Gross Profit | $555.20M | $90.47M |
| Operating Income | -$98.60M | -$21.44M |
| Pretax Income | -$111.80M | -$14.45M |
| Net Income | -$112.60M | -$22.46M |
| EBITDA | -$48.40M | -$16.91M |
| EPS (Diluted) | -$1.19 | -$0.83 |
Margins
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Gross Margin | 68.8% | 52.3% |
| Operating Margin | -12.2% | -44.5% |
| Pretax Margin | -13.9% | -13.0% |
| Profit Margin | -14.0% | -39.2% |
| EBITDA Margin | -6.00% | -31.3% |
Returns
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -32.5% | -53.1% |
| Return on Assets (ROA) | -17.1% | -41.0% |
| Return on Invested Capital (ROIC) | -22.8% | -32.0% |
| Return on Capital Employed (ROCE) | -19.4% | -37.8% |
Growth
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -3.16% | 6.01% |
| Revenue Growth (3Y CAGR) | 6.72% | 2.25% |
| Revenue Growth (5Y CAGR) | -0.63% | 6.42% |
Balance sheet
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $115.20M | $62.42M |
| Total Debt | $120.70M | $120.13M |
| Net Cash (Debt) | -$5.50M | $15.68M |
| Net Cash Per Share | -$0.06 | $0.65 |
| Equity (Book Value) | $303.90M | $48.79M |
| Book Value Per Share | $3.18 | $1.36 |
| Tangible Book Value | $117.80M | $23.06M |
| Working Capital | $158.30M | $75.77M |
Financial position
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Current Ratio | 2.21 | 3.30 |
| Quick Ratio | 1.72 | 2.39 |
| Debt / Equity | 0.40 | 0.51 |
| Interest Coverage | -6.01 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Operating Cash Flow | $7.70M | -$12.35M |
Efficiency
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Asset Turnover | 1.23 | 0.38 |
| Inventory Turnover | 8.48 | 2.67 |
| Revenue Per Employee | $298.74K | $398.96K |
| Profits Per Employee | -$41.70K | -$732.08K |
| Employee Count | 2,700 | 73 |
Dividends and yields
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Earnings Yield | -28.0% | -21.2% |
Shares
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Shares Outstanding | 95,649,600 | 59,128,900 |
| Shares Change (YoY) | 2.57% | 11.1% |
| Shares Change (QoQ) | 1.27% | 0.54% |
| Float | 88,793,400 | 48,744,500 |
| Shares Held by Insiders | 7.17% | 11.8% |
| Shares Held by Institutions | 94.1% | 59.4% |
Taxes
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Income Tax | $800.00K | $91.50K |
Scores
| Measure | Myriad Genetics | Industry median |
|---|---|---|
| Altman Z-Score | -0.86 | 0.10 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -5.37 | -2.62 |
Calculated by StockData from Myriad Genetics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.